Immunocytochemical markers in stage I lung cancer: relevance to prognosis.

1997309 citationsJournal Article

Authors

Ugo Pastorino · Royal Brompton Hospital

Salvatore Andreola · Imperial College London

Elda Tagliabue · Fondazione IRCCS Istituto Nazionale dei Tumori

Francesco Pezzella · Imperial College London

Marco Incarbone · MultiMedica

Gabriella Sozzi · Fondazione IRCCS Istituto Nazionale dei Tumori

Marc Buyse

Abstract

Our findings do not support a relevant prognostic role of immunocytochemical markers in NSCLC. The evidence is not sufficient to alter clinical practice or even to restrict clinical trials of adjuvant treatments to predefined biologic subsets of patients.

Topics & Keywords

Cancer, Hypoxia, and Metabolism Cancer Cells and Metastasis RNA modifications and cancer

UN Sustainable Development Goals

No poverty

Publication Details

Published in: Journal of Clinical Oncology

Volume 15, Issue 8, pp. 2858-2865

DOI: 10.1200/jco.1997.15.8.2858

Field-Weighted Citation Impact: 6.10